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Summary
Guidelines assist practitioners in the management of opioid dependence, however, important day-to-day issues in the field 
must be addressed, such as “Which medication to use, how to start, how to dose, when to stop, how to manage compli-
cations and comorbidities?”.  The workshop aimed to define the approach to managing the gap between guidelines for 
opioid dependence management and the real life clinical situations. 6 expert speakers in the field of opioid dependence 
management presented detailed guidelines examination, the evidence for the guidelines, and expert clinical experience 
highlighting the practical needs for prescribers in opioid dependence management for individualised patient care and 
comorbidities. Results: Sufficient evidence supports the treatment of opioid dependence, but evidence gaps remain which 
are likely to be important in guiding specific decisions about individual patient care. Clinical experience is vital to bridge 
the gaps between Guidelines advice, effective individual patient tailored care in the treatment of opioid dependence.
Conclusions: It is important to tailor care to individual patient needs under the consideration of evidence based facts. Ini-
tial recommendations for treatment directed by a system based on tolerance to opioids, level of existing psychopathology, 
and abuse of other substances could bridge the gap between Guidelines and the real life clinical setting.
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1. Introduction
Opioid maintenance treatment with opioid ago-
nists is widely used for the pharmacological manage-
ment of opioid dependence. Moving from a previous 
era when the question was, “Should we treat?”, the 
relevant questions are now focused on, “How should 
we treat?”. The present discussion aims to define evi-
dence, experience and gaps for day-to-day treatment 
decisions in opioid dependence.
Not all treatment decision processes are ad-
equately directed by Guidelines for the management 
of opioid dependence. It is important to tailor care to 
specific individual patient needs. The following ques-
tions should be asked when considering the value of 
Guidelines and applying their advice in day-to-day 
care: What is the basis of the guidance? What is the 
evidence? What are the gaps? What is the underlying 
psychiatric comorbidity?
The discussion is informed by a detailed analy-
sis of Guidelines creation and also with experienc-
es of clinical experts managing the real life clinical 
situations, individualised care and comorbidities in 
opioid dependence. 
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2. Discussion
2.1. Evidence for Guidelines in opioid management: 
account of World Health Organisation (WHO) 
experience
The WHO ATLAS on Drug & Alcohol Treat-
ment Service [17] identifies opioid dependence as the 
most common reason for seeking help for addiction. 
This need was in part the drive for development of 
WHO Guidelines, which met the needs of experts in 
a broad range of settings trying to manage opioid de-
pendence. The WHO Guidelines for psychosocially 
assisted pharmacological treatment of opioid depend-
ence [3] were published in 2009.
These Guidelines were developed according to 
WHO process for clinical Guidelines [16] and are 
based on systematic reviews of the literature using the 
GRADE process to determine the quality of the evi-
dence with support of procedural and content experts. 
The work assessed treatment modalities with use of 
Opioid agonists, antagonists and other medicines. 
The approach used “PICO” format [1]: for this Popu-
lation (opioid dependent), does Intervention A (i.e. 
methadone), Compared to intervention B (i.e. opioid 
withdrawal) result in better Outcomes of interest (i.e. 
mortality, quality of life)?
Questions addressed include: benefits of opioid 
maintenance compared to opioid withdrawal with 
possible antagonist, benefits of opioid maintenance 
including choice of opioid (methadone, buprenor-
phine), supervised or unsupervised dosing, high dose 
or low dose treatment, and value of psychosocial sup-
port. Opioid withdrawal was assessed to determine 
medication choice in opioid withdrawal (methadone, 
buprenorphine, others) with or without psychosocial 
support and/or antagonists for relapse prevention.
The guidance aimed to define evidence for prac-
tical questions. The systematic review identified a set 
of studies meeting key criteria.
The process identified that there was relatively 
strong evidence to compare buprenorphine versus 
methadone; there was little data to compare super-
vised and unsupervised dosing. There was limited 
data defining best practice on impact on quality of 
life, for maintenance therapy versus withdrawal. 
Important questions are outstanding for manage-
ment of prescription opioid dependence: the predomi-
nant form of opioid dependence. Strong prescription 
opioids have similar mortality to heroin dependence, 
but in a different population of patients and with dif-
ferent interventions needed.
Of the thousands of “hits” in the systematic 
search fewer than 1 in 100 sources were relevant to 
the development of Guidelines. There are a number of 
reasons why the process identified so little evidence 
for important questions: studies were limited to small 
numbers of patients, often lacking intention to treat 
analysis and follow up. Often studies showed poor 
adherence to CONSORT for their design. 
To improve the understanding of opioid depend-
ence management and to better inform clinical decisions, 
there is a need for international collaborations to deliver 
larger overpowered studies to generate more data. There 
is need for consensus building in the research commu-
nity on what research questions need answers (table 1), 
Table 1 Outstanding research questions: Decision making in opioid dependence management
Area of focus Key question
Opioid maintenance vs. opioid 
withdrawal (+/- antagonist)
• What is the impact on quality of life?
• What is evidence for maintenance versus detox and long acting antagonist?
• How to manage patient selection?
Opioid maintenance – how to 
provide treatment?
• Which opioid agonist to choose, in which situation? (Buprenorphine versus 
buprenorphine/naloxone) 
• Supervised versus unsupervised – very little data on unsupervised
• High dose versus low dose – little data on higher doses of buprenorphine 
(>8mg)
• +/- Psychosocial support – little data on social support/web based interven-
tions
Opioid withdrawal – how to 
manage?
• What medication to manage opioid withdrawal (what to use when methadone/ 
buprenorphine/ clonidine are not available)?
• Withdrawal from maintenance treatment and prescription opioids
• +/- Psychosocial support – role of residential rehabilitation
• +/- Antagonist for relapse prevention – long acting antagonists
Opioid overdose prevention • Distribution of naloxone
• Use of opioids in chronic non-malignant pain
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which trials are needed. Consensus building on trial 
design and outcome measurement issues to drive inter-
national collaboration on clinical research via clinical 
trials network would be of great value.
2.2. Australian Guidelines for the treatment of opiate 
addiction
The treatment for opioid dependence in Aus-
tralia has a well-defined basis. Since the Dole and 
Nyswander studies in 1964 and the introduction of 
Opioid Agonist Therapy in Australia in 1969, there 
is recognition of the need for programmed interven-
tion in opioid dependence. Treatment was endorsed 
nationally in 1985 and there were 46,697 pharmaco-
therapy clients by 2012. The unmet need for heroin 
dependence is around 40,000 cases [2].
The basis of the Guidelines come from the 
1990’s: the noted growth in heroin use and relat-
ed ‘crises’ such as overdose, risk of viral infection 
(HIV, HCV) presented a challenge to expand treat-
ment numbers quickly. To deliver the increase in care 
needed it was necessary to expand into private sector 
involving GPs & pharmacies.
The evolution of treatment in Australia includes 
the introduction of Naltrexone, registered in 1999 and 
addition of buprenorphine, which was introduced in 
2002. The use of buprenorphine was modelled on 
methadone treatment in Australia but was preferred 
by some clinicians over methadone because of the in-
herently lower risk profile medication. Early concerns 
of misuse (injecting of tablets) led to the introduction 
of the combination product, Suboxone® (2005) as 
strategy to reduce misuse [8].
The recent revision of Guidelines in Australia 
aimed to combine different existing guidance docu-
ments into an integrated resource, more clearly ev-
idence-based and reflecting new experience. The 
process aimed to provide broad policy context and 
framework for Medication Assisted Treatment for 
opioid dependence while promoting national consist-
ency with jurisdictional responsibilities.
The Guidelines are based on a review of evi-
dence using the NHMRC [9] systematic approach. 
Not all evidence is graded by the standard approach: 
the Guidelines include evidence that is based on the 
standard of care, clinical experience consensus or 
regulatory requirement.
The Guidelines reflect agreement on areas in-
cluding induction doses, stabilisation regimes, main-
tenance doses, role of urine drug screening, and treat-
ment in pregnancy.  Areas where evidence is evolving 
include: use of take away doses, withdrawal regimes 
from maintenance treatment, prescription opioid de-
pendence treatment, and methadone to buprenorphine 
transfer. 
For takeaway doses and unsupervised dosing 
the evidence base is limited. Most studies have been 
conducted in the context of supervised dosing. It is 
important to differentiate takeaway doses from unsu-
pervised dosing. In the family context where there is 
a responsible adult, this can enable a takeaway dose 
to be supervised in many cases. When defining the 
access to medicines with takeaway doses and unsu-
pervised dosing, policy must strike a balance between 
patient rights and access to safe and effective treat-
ment, against medication diversion concerns. 
Takeaway dosing is not usually available in the 
first 3 months of treatment after which it may be ap-
propriate for 1 to 6 consecutive doses; number of con-
secutive days offered as takeaway doses is dependent 
on jurisdictional regulations and a patient risk assess-
ment. This type of dosing is suitable for clients as-
sessed as stable. The risk assessment is based on: reg-
ular attendance at appointments, urine drug screens 
provided when requested, no or infrequent additional 
opioid use, benzodiazepine use absent or low levels 
and stable, no alcohol abuse, no or infrequent use 
of stimulants, no recent intoxicated presentations or 
overdoses (in prior 3 months) and no recent missed 
doses. 
Unsupervised dosing improves client’s reinte-
gration into daily activities, reduces cost of treatment, 
reduces stigma. There are risks to manage; risk de-
pends on frequency and number of consecutive takea-
ways. In approving single occasion takeaways, the 
prescriber needs to place emphasis on safety of client 
and family.
The Guidelines are informed by evidence, clini-
cal experience and patient expectations. It is impor-
tant to reflect jurisdictional differences and resource 
or capability limits, size and nature of problem and 
Regulatory control. The Guidelines are an advance 
but there are areas where evidence is still required. 
The picture of need is changing: prescribed medicines 
containing opioids are now the source of dependence 
for the majority of new clients entering treatment.
2.3. Recognising the clinical problems in opioid 
maintenance treatment and expert recommenda-
tions for clinical management 
The impact of opioid dependence is well de-
scribed. In Europe, there are 1.4 million users as de-
- 36 -
Heroin Addiction and Related Clinical Problems 16(4): 33-40
fined according to EMCDDA definition; Opioid de-
pendence is related to 90% of drug related overdoses 
in Europe with a high mortality [15]. The Mortality 
rate is increased compared to age matched group in 
predominantly young men, with  overdose deaths [5] 
and  suicide rate 14 times higher than the general pop-
ulation [7].   HIV and Hepatitis C infections are well 
known somatic comorbidities in this population (The 
prevalence of hepatitis C virus antibodies among in-
jecting drug users is varying between 22% and 83% 
across European countries according to EMCDDA 
evidence).
Treatment options are well defined for detoxifi-
cation and maintenance. For detoxification, treatment 
with methadone or buprenorphine is more effective 
than detoxification with α2 adrenergic agonists. De-
toxification should always be followed by planned re-
lapse prevention as detoxification increases mortality 
risk. 
For opioid maintenance therapy the two main-
stays of medication  are oral methadone and sublin-
gual buprenorphine including the combination prod-
uct buprenorphine/ naloxone. Other medication, such 
as slow release oral morphine (SROM) show efficacy 
but use is limited to some countries [18,19]. Evidence 
shows that methadone reduces heroin use, injection 
and needle sharing, and is more effective at 60-120 
mg/ day dose [2]. Buprenorphine or Buprenorphine/ 
Naloxone are safe and effective in maintenance treat-
ment as an alternative to methadone; clinical practice 
determines that higher doses (> 8 mg) are more ef-
fective. Combination products have advantages when 
misuse is a concern.
Based on the knowledge of effective treatment, 
individualised care should be prepared for all patients 
based on best outcomes predictors. These include: 
higher versus lower dosages of opioid medication, 
matching services to patient needs (range of servic-
es, individualised care program, special care for co-
morbidity and poly-drug dependence), flexibility of 
regimes (intake, controls) with appropriate staff at-
titudes and competence.
There are different care models in Europe; 
Guidelines do not clarify which approach is opti-
mal. In Austria, France, Germany, UK care is mainly 
general practitioner provided. In Denmark, France, 
Italy, Netherlands, Portugal, Spain care is provided 
in specialist centres, and in Finland, Greece, Sweden, 
Norway care is provided in a small number of dedi-
cated specialist centres. There are advantages of both 
systems as set out in table 2. An integrated model of 
both central and local services has many benefits – it 
avoids stigma of going to the specialist services but 
provides opportunity to escalate input if needed. The 
care model in opioid dependence should be recon-
sidered so it is less restrictive and is similar to other 
chronic disease: Guidelines should assist in this area. 
An optimal combination of a mix of services for de-
pendence management can be set up for each indi-
vidual patient. This can range from self-care in stable 
situations through to the need for complex, expert in-
put in the residential setting. The frequency of need 
Table 2 Comparison of care models in opioid dependence management




• “Family doctor”- prevention & early treat-
ment initiation
• May be cost effective
• Integration into mainstream medicine is 
possible due to general nature of the gene-
ral practitioner-based service
• Decentralized, possible greater access
• More capacity to treat, offer services in 
addiction
• Low threshold for acceptance to treatment
• Drug-drug interaction can be carefully 
managed from holistic picture
• Limited psychiatry education in some cases 
– comorbidity may be difficult to manage
• Time for education may be limited in the 
busy GP setting
• Lack of multi-professional support through 




• Pharmacist with specialist skills available
• Psychiatrist available to consult on comor-
bidities 
• Nurses, specialist trained
• Psychologist available
• Social worker available
• High threshold - selected group
• Often by nature of clinical service, centrali-
zed in large cities
• Limited capacity may be a problem
• Often expensive
• "Stigma-addiction” clinic attendance may 
be a problem for patients/ clients
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likely to have a mood or anxiety disorder and more 
likely to have a borderline personality disorder and 
men are more likely to have an antisocial personality 
disorder [6].
Lifetime prevalence of mood disorders in those 
with opioid dependence is higher than in the general 
population [12]. Independent major depression disor-
ders are more frequent than substance-induced disor-
ders and more frequent in women than in men. The 
occurrence of independent major depression disor-
ders is almost three times higher in opioid dependent 
women than in the general female population. 
The presence of major depression at treatment 
intake or during follow-up in opioid dependence re-
sults in a worse clinical outcome compared to the 
treatment of opioid dependence without depression. 
This means a greater risk of relapse in both drug use 
and psychiatric disorders. The main clinical differ-
ences between induced and primary depression in 
opioid users are described in table 3.
Due to the clinical relevance of comorbid de-
pression there is a need for specific treatment of 
depression as a comorbidity in opioid dependence. 
Figure 1 defines a joined up approach to the manage-
ment of depression in opioid dependence [10, 13]. 
Psychological and pharmacological interventions 
for care and input along with the costs of service will 
vary for each patient, over time. Special populations 
such as people at risk of misuse and worsening out-
comes have a need for individualised care. Special 
tailoring of care should also be provided to patients 
within the criminal justice system [4], and to pregnant 
women [14]. 
2.4. The influence of diagnosing and treating psychi-
atric comorbidities on successful outcomes in 
management of opioid dependence 
It is important to recognise the presence of other 
psychiatric comorbidities in the tailoring of individual 
treatment in opioid dependence management because 
these increase the severity of psychopathology (i.e. 
number of emergency admissions, suicides…), fre-
quency of risk behaviour and related infections (i.e. 
HIV, HCV), psychosocial impairment, and tendency 
to criminal behaviours compared to opioid dependent 
subjects without these comorbid disorders.
Epidemiological evidence shows psychiatric co-
morbidities are common. Most frequent are depres-
sion, anxiety and personality disorder. Although psy-
chiatric comorbidity occurs in females and males, it 
is more frequent in females [12]. Women are twice as 
Figure 1. Management of depression coexisting with substance misuse: a joined up approach of psychological and 
pharmacological intervention
16 June 2014 
app l ied  s t ra teg ic     1 
Figure 1 Management of depression coexisting with substance misuse: a joined up 
approach of psychological and pharmacological intervention 
 
 
Clinical practice: algorithm for management of substance use disorder 
Presumption: 
MD independent of SUD 
Mild/Moderate Severe 
Specific treatment for SUD 
Abstinence or reduction  
in consumption 
Pharmacological treatment specific for MD 
Outpatient treatment Hospital treatment 





treatment for SUD: 
•  Methadone 
•  Naltrexone Persistence of symptoms 












MD induced by SUD 
1 
Torrens et al, 2011; Nunes and Levin, 2008 
- 38 -
Heroin Addiction and Related Clinical Problems 16(4): 33-40
5. Conclusions 
There are important gaps in the evidence to be 
filled, which might direct specific decisions about in-
dividual care for each patient. There is sufficient evi-
dence supporting the treatment of opioid dependence; 
clinical experience is essential to complete the gaps 
between advice in Guidelines and successful care of 
individual patients. In the practical setting a simple 
system may be of use to clinicians. A system based 
on tolerance to opioids, level of existing psychopa-
thology (how strong is the dependence?) and abuse of 
other substances can be used to make initial recom-
mendations for treatment in maintenance. The system 
and potential recommendations in model cases are 
defined in table 4.
This system and potentially other similar ap-
proaches are useful starting points for tailoring care 
to the needs of individual patients and moving from 
the Guidelines to the real life in the clinical setting.
may have beneficial impact on depression and opioid 
dependence, however the evidence is not strong. It is 
important to understand the safety and efficacy pro-
files of pharmacological interventions for depression 
and opioid dependence.
A major analysis of pooled evidence [11] deter-
mined there was low evidence supporting the clinical 
use of antidepressants for the treatment of depressed 
opioid addicts in treatment with opioid agonists 
(methadone). This analysis considered both the pos-
sible “Improvement of depressive symptoms by anti-
depressants” and “Improvement of opioid use by anti-
depressants”. This meta-analysis did not demonstrate 
a positive benefit for either.
It is important to consider medication safety 
when treating depression and opioid dependence. 
Specific interactions of antidepressant medications 
such as Tricyclic antidepressants are well described 
and include increased adverse events and risk of 
overdose, with potential for abnormalities of cardiac 
rhythm in some cases. There is a further need for evi-
dence to guide treatment of both conditions: opioid 
dependence and comorbidities, such as depression.
Table 4 A proposed treatment system and potential recommendations, to bridge the gaps between Guidelines and 
successful patients in the treatment of opioid dependence.
Example Tolerance to opioids Severity of psychopa-thology




Patient 1 Low Low level of existing psychopathology Use of cocaine Buprenorphine products
Patient 2 Medium High level of existing psychopathology Use of alcohol Buprenorphine products
Patient 3 High High level of existing psychopathology Use of benzodiazepines Methadone
Table 3 Criteria for diagnosis of depression as a comorbidity with opioid dependence
Type Patient profile Frequently associated symptoms Prognostic indicators
Depression indu-





• Emergence of depressive symptoms:
• During an escalation of SUD consum-
ption, or
• During a significant drop in SUD con-
sumption
• History of alcoholism in the 
family






• White or 
Hispanic
• Elderly
• History of depression independent of 
SUD
• History of good response to antidepres-
sant treatment for previous episodes
• Family history of depression






• Elderly • Increase in depressive 
symptoms throughout life
• History of suicide attempts
• Comorbid anxiety
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